m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0219)

Name	Myelodysplastic neoplasms
ICD	ICD-11: 2A4Z

References

Ref 1	The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44. doi: 10.1158/1535-7163.MCT-12-0302. Epub 2012 Jul 9.

Cite M6AREG

S. P. Liu, L. Chen, Y. T. Zhang, Y. Zhou, Y. He, Z. Chen, S. S. Qi, J. Y. Zhu, X. D. Chen, H. Zhang, Y. C. Luo, Y. Q. Qiu, L. Tao*, F. Zhu*. M6AREG: m6A-centered regulation of disease development and drug response. Nucleic Acids Research. 2022 Sep 22;gkac801. PMID: 36134713

Correspondence

Prof. Feng ZHU

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

Prof. Shuiping Liu

School of Pharmacy, Hangzhou Normal University, Hangzhou, China

m6A-centered Disease Response Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map